Artelo Biosciences, Inc.

Equities

ARTL

US04301G5080

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 31/05/2024 BST			5-day change	1st Jan Change
1.37 ^USD	+3.79%		-4.86%	-2.14%

05-13	Artelo Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-23	Transcript : Artelo Biosciences, Inc. - Special Call

Artelo Biosciences, Inc. Reports Positive Pre-Clinical Results for Lead Program in Cancer-Related Cachexia

April 13, 2022 at 01:30 pm

Artelo Biosciences, Inc. announced that ART27.13, a peripherally selective G-Protein Coupled Receptor (GPCR) full agonist currently in clinical development for cancer-related anorexia, shows promising pre-clinical results in protecting human muscle cells from cancer-induced muscle degeneration (cachexia) via a CB2 mediated mechanism of action.

Latest news about Artelo Biosciences, Inc.

Artelo Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Transcript : Artelo Biosciences, Inc. - Special Call	04-23
Artelo Biosciences, Inc. Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy	04-23	CI
Artelo Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-25	CI
Top Premarket Gainers	02-06	MT
Artelo Biosciences, Inc. Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy	01-23	CI
Artelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023	11-02	CI
Transcript : Artelo Biosciences, Inc. - Special Call	11/10/23
Artelo Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Transcript : Artelo Biosciences, Inc. - Special Call	11/07/23
Artelo Biosciences Files $75 Million Mixed Shelf	07/07/23	MT
Artelo Biosciences Selects for Oral Presentation to Report Positive Research Findings on Art12.11	07/06/23	CI
Artelo Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
Artelo Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss	02/02/23	CI
Artelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	08/11/22	CI
Top Premarket Decliners	17/08/22	MT
Top Midday Gainers	16/08/22	MT
Artelo Biosciences, Inc. Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5	16/08/22	CI
HC Wainwright Lowers Price Target for Artelo Biosciences to $55 From $60, Maintains Buy Rating	12/08/22	MT
Artelo Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	09/08/22	CI
Artelo Biosciences Enrolls First Three Cohorts in Cancer-Related Anorexia, Weight-Loss Study	19/07/22	MT
Artelo Biosciences, Inc. Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13	19/07/22	CI
Artelo Biosciences, Inc. announced that it has received $0.9672 million in funding	19/05/22	CI

Chart Artelo Biosciences, Inc.

Duration

Period

More charts

Company Profile

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. It is developing a dual cannabinoid (CB) agonist that targets both the CB1 and CB2 receptors. This synthetic small molecule program is a G protein-coupled receptor (GPCR) designated ART27.13. ART27.13 is a potential treatment for anorexia associated with cancer. Its second program ART26.12, is a small molecule lead product candidate from its platform of inhibitors of fatty acid binding proteins, notably Fatty Acid Binding Protein 5 (FABP5), which is undergoing pre-clinical research as a potential cancer therapeutic, for pain and inflammation, and in anxiety-related disorders, including post-traumatic stress disorder.

Sector

Biotechnology & Medical Research

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.37 USD

Average target price

22.5 USD

Spread / Average Target

+1,542.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ARTELO BIOSCIENCES, INC.	-2.14%	4.42M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs